House investigation says FDA approval process of Alzheimer's drug was 'rife with irregularities'
By Jen Christensen
Seeking maximum profits, Biogen set an 'unjustifiably high price' for Alzheimer's treatment, investigation finds
By Adam Feuerstein & Damian Garde
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drug
By Ahmed Aboulenein
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
By Pam Belluck
8 takeaways from investigation of Alzheimer's drug approval - STAT
By Adam Feuerstein, Damian Garde & Rachel Cohrs